The mission of the Endocannabinoid System Network (ECSN) is to serve as a multifaceted educational resource that will help scientists and clinicians understand and communicate the mechanisms and functions of the endocannabinoid system (ECS)—integrating knowledge of the cellular/molecular basis with the neural and systemic effects impacting cardiovascular and metabolic risk factors and their underlying pathophysiology.
http://www.endocannabinoid.net/
www.endocannabinoid.net
Suggested Reading
Click on the link below to access journal articles related to the slide presentation.
Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1014.
Astrup A, Toubro S. When, for whom and how to use sibutramine? International Journal of Obesity. 2001;25 (Suppl 4):S2-S7.
Despres JP, Golay A, Sjostrom L, for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-2134.
Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838-2843.
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359.
Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C; for the Conference Participants. NHLBI/AHA Conference Proceedings: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004;109:433-438.
Hanley AJG, Willians K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study. Diabetes Care. 2002;25(7):1177-1184.
Hu FB, Stamfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134.
Kirkham TC, Williams CM, fezza F, Dimarzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British J of Pharmacology. 2002;136:550-557.
Knowler WC, Barett-Connor, Fowler SE, Hamman RF, et al, for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: The San Antonio Heart Study. Diabetes Care. 2003;26:3153-3159.
Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
Mokdad AH, Ford ES, Bowman BA. The continuing increase of diabetes in the U.S. Diabetes Care. 2001; 24:412.
Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282:1519-1522.
Pi Sunyer FX. Aronne LJ, Heshmati HM, devin J, Rosenstock J, for the RIO-Nofrth America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006; 295:761-775.
Scheen AJ, et al. Lancet. 2006;368:1660-1672Scheen AJ, et al. Lancet. 2006;368:1660-1672
